GILEAD SCIENCES, INC.
For the period ended Mar 31, 2026. Filed May 7, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 7, 2026
GILD$170.87+0.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| (in millions, except per share amounts) | 2026 | 2025 |
| Revenues: | ||
| Product sales | $6,946 | $6,613 |
| Royalty, contract and other revenues | 14 | 54 |
| Total revenues | 6,960 | 6,667 |
| Costs and expenses: | ||
| Cost of goods sold | 1,445 | 1,540 |
| Research and development expenses | 1,372 | 1,379 |
| Acquired in-process research and development expenses | 107 | 253 |
| Selling, general and administrative expenses | 1,451 | 1,258 |
| Total costs and expenses | 4,374 | 4,430 |
| Operating income | 2,586 | 2,237 |
| Interest expense | 240 | 260 |
| Other (income) expense, net | (235) | 328 |
| Income before income taxes | 2,580 | 1,649 |
| Income tax expense | 559 | 334 |
| Net income | $2,021 | $1,315 |
| Basic earnings per share | $1.63 | $1.06 |
| Diluted earnings per share | $1.61 | $1.04 |
| Shares used in basic earnings per share calculation | 1,242 | 1,246 |
| Shares used in diluted earnings per share calculation | 1,254 | 1,259 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.